Medical News Observer

Key Points

• Bladder AI is FDA-cleared under 510(k) for use as a Class II medical device, ensuring it meets standards for safety and effectiveness compared to existing devices.
• Tested on 122 subjects, it has demonstrated high accuracy and reliability.
• Integrating Bladder AI in medical diagnostics may enhance the precision and functionality of clinical assessments.

Device Information

Bladder AI is a standalone software designed as a medical device (SaMD) that facilitates image-based assessment of bladder ultrasound images for patients aged two years or older. The primary function of this AI software is to aid trained healthcare providers by simplifying the workflow during evaluation, quantification, and reporting of bladder ultrasound images. It features machine learning (ML) based semi-automatic landmark placements, bladder dimension, volume measurements, and report generation capabilities.

Manufacturer Information

Exo Imaging developed the software device. 

Regulatory Approval Information

Bladder AI has received clearance from the U.S. Food and Drug Administration (FDA) under the 510(k) premarket notification process. Classified under regulation 21 CFR 892.2050, it is a Class II device with the product code QIH. This clearance shows that the device substantially equals legally marketed predicate devices, enabling its marketing and sales in the United States.

Indications

Bladder AI is indicated for quantifying bladder volume from ultrasound images in patients aged two years or older. This device uses machine-learning techniques to aid these measurements, ensuring precise evaluations.

Contraindications

Regarding Bladder AI, the documentation for this device does not provide specific details regarding what conditions would make it inappropriate to use ultrasound imaging or machine-learning assistance.

Study Results

Researchers evaluated the clinical performance of Bladder AI on 122 subjects using various ultrasound devices. The device demonstrated high accuracy and reliability, with an intraclass correlation coefficient (ICC) of up to 0.98. These results support the device’s consistent performance across a diverse range of patient demographics and device settings.

Limitations

Despite its efficacy, the device could have limitations, including its dependency on proper image quality and user competence in operating the ultrasound technology and the software. Also, as with any automated system, there is a risk of over-reliance, which could potentially overlook atypical cases not well-represented in the training data.

Conclusion

Bladder AI by Exo Imaging is a robust tool designed to enhance the accuracy and efficiency of bladder volume assessments using ultrasound imaging. FDA clearance confirms its substantial equivalence to existing technologies, representing a significant advancement in medical imaging software. It has proven effective and reliable in clinical testing, demonstrating high accuracy in volume measurement across a diverse patient population.

Future Implications

This technology’s successful implementation and adoption can lead to broader advancements in medical diagnostics. As machine learning technology continues to evolve, future iterations of this device could offer even greater precision, additional functionalities, and more user-friendly interfaces. 

The ongoing development of such technologies is likely to further integrate AI into everyday clinical practices, potentially transforming diagnostic procedures in urology and beyond. Furthermore, the data gathered from the widespread use of such systems could provide invaluable insights into population health trends and lead to improved strategies for managing bladder health.

Reference

• “Bladder AI (AIBV01) K230497 510(k) Premarket Notification.” Accessed Online. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K230497.
• clariushd. “Bladder AI – Automated Bladder Volume Calculation | Clarius,” . Accessed Online. https://clarius.com/technology/.